Ken Fisher's LLY Position Overview
Ken Fisher (via Fisher Asset Management, LLC) currently holds 4.61 M shares of Eli Lilly and Company (LLY) worth $4.95 B, representing 1.69% of the portfolio. First purchased in 2013-Q4, this long-term strategic position has been held for 49 quarters.
Based on 13F filings since 2013, Ken Fisher has maintained a long-term strategic position in LLY, representing a significant commitment to this investment thesis. Largest addition occurred in Q1 2022, adding 521,295 shares. Largest reduction occurred in Q3 2022, reducing 2.03 M shares.
Analysis based on 13F filings available since 2013 Q2
Ken Fisher's Eli Lilly and Company (LLY) Holding Value Over Time
Track share changes against reported price movement
Quarterly Eli Lilly and Company (LLY) Trades by Ken Fisher
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +153,265 | Add 3.44% | 4.61 M | $1074.68 |
| Q3 2025 | +150,595 | Add 3.50% | 4.45 M | $763.00 |
| Q2 2025 | -1.14 M | Reduce 20.89% | 4.3 M | $779.53 |
| Q1 2025 | +202,338 | Add 3.86% | 5.44 M | $825.91 |
| Q4 2024 | +178,007 | Add 3.52% | 5.24 M | $772.00 |
| Q3 2024 | +169,391 | Add 3.46% | 5.06 M | $885.94 |
| Q2 2024 | +195,855 | Add 4.17% | 4.89 M | $905.38 |
| Q1 2024 | +150,766 | Add 3.32% | 4.69 M | $777.96 |
| Q4 2023 | +85,015 | Add 1.91% | 4.54 M | $582.92 |
| Q3 2023 | +220,032 | Add 5.19% | 4.46 M | $537.13 |
| Q2 2023 | +141,541 | Add 3.46% | 4.24 M | $468.98 |
| Q1 2023 | +101,303 | Add 2.54% | 4.1 M | $343.42 |
| Q4 2022 | +90,761 | Add 2.33% | 3.99 M | $365.84 |
| Q3 2022 | -2.03 M | Reduce 34.23% | 3.9 M | $323.35 |
| Q2 2022 | -1.57 M | Reduce 20.91% | 5.93 M | $324.23 |
| Q1 2022 | +521,295 | Add 7.47% | 7.5 M | $286.37 |
| Q4 2021 | +470,522 | Add 7.23% | 6.98 M | $276.22 |
| Q3 2021 | +502,075 | Add 8.35% | 6.51 M | $231.05 |
| Q2 2021 | +502,005 | Add 9.11% | 6.01 M | $229.52 |
| Q1 2021 | +470,518 | Add 9.34% | 5.51 M | $186.82 |
| Q4 2020 | +359,479 | Add 7.68% | 5.04 M | $168.84 |
| Q3 2020 | +179,334 | Add 3.99% | 4.68 M | $148.02 |
| Q2 2020 | +164,530 | Add 3.80% | 4.5 M | $164.18 |
| Q1 2020 | -77,563 | Reduce 1.76% | 4.33 M | $138.72 |
| Q4 2019 | +105,613 | Add 2.45% | 4.41 M | $131.43 |
| Q3 2019 | +178,464 | Add 4.32% | 4.31 M | $111.83 |
| Q2 2019 | +192,702 | Add 4.90% | 4.13 M | $110.79 |
| Q1 2019 | +100,704 | Add 2.63% | 3.94 M | $129.76 |
| Q4 2018 | +107,857 | Add 2.89% | 3.83 M | $115.72 |
| Q3 2018 | +16,604 | Add 0.45% | 3.73 M | $107.31 |
| Q2 2018 | +180,855 | Add 5.12% | 3.71 M | $85.33 |
| Q1 2018 | +219,612 | Add 6.64% | 3.53 M | $77.37 |
| Q4 2017 | +200,587 | Add 6.45% | 3.31 M | $84.46 |
| Q3 2017 | +119,491 | Add 4.00% | 3.11 M | $85.54 |
| Q2 2017 | +408,059 | Add 15.81% | 2.99 M | $82.30 |
| Q1 2017 | +266,698 | Add 11.52% | 2.58 M | $84.11 |
| Q4 2016 | +218,358 | Add 10.42% | 2.31 M | $73.55 |
| Q3 2016 | +111,494 | Add 5.62% | 2.1 M | $80.26 |
| Q2 2016 | +238,524 | Add 13.66% | 1.98 M | $79.14 |
| Q1 2016 | +274,271 | Add 18.63% | 1.75 M | $75.53 |
| Q4 2015 | +232,709 | Add 18.78% | 1.47 M | $84.26 |
| Q3 2015 | +210,378 | Add 20.44% | 1.24 M | $83.69 |
| Q2 2015 | +233,121 | Add 29.29% | 1.03 M | $83.49 |
| Q1 2015 | +216,917 | Add 37.46% | 795,909 | $72.65 |
| Q4 2014 | +459,182 | Add 383.26% | 578,992 | $68.99 |
| Q3 2014 | +115,595 | Add 2742.47% | 119,810 | $64.85 |
| Q2 2014 | +67 | Add 1.62% | 4,215 | $62.16 |
| Q1 2014 | -281 | Reduce 6.34% | 4,148 | $58.82 |
| Q4 2013 | +4,429 | New Buy | 4,429 | $51.03 |
Ken Fisher's Eli Lilly and Company Investment FAQs
Ken Fisher first purchased Eli Lilly and Company (LLY) in Q4 2013, acquiring 4,429 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ken Fisher has held Eli Lilly and Company (LLY) for 49 quarters since Q4 2013.
Ken Fisher's largest addition to Eli Lilly and Company (LLY) was in Q1 2022, adding 7,504,205 shares worth $2.15 B.
According to the latest 13F filing for Q4 2025, Ken Fisher's firm, Fisher Asset Management, LLC, owns 4,606,327 shares of Eli Lilly and Company (LLY), valued at approximately $4.95 B.
As of the Q4 2025 filing, Eli Lilly and Company (LLY) represents approximately 1.69% of Ken Fisher's publicly disclosed stock portfolio, making it one of their key holdings.
Ken Fisher's peak holding in Eli Lilly and Company (LLY) was 7,504,205 shares, as reported at the end of Q1 2022.